{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T07:01:14Z","timestamp":1720335674873},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/hco.0b013e3283642a4c","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T11:24:09Z","timestamp":1376047449000},"page":"584-591","source":"Crossref","is-referenced-by-count":2,"title":["Drug treatment of obesity in the cardiovascular patient"],"prefix":"10.1097","volume":"28","author":[{"given":"Marietta","family":"Charakida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Finer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210204","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.cjca.2012.01.001","article-title":"The obesity epidemic and its impact on hypertension.","volume":"28","author":"Nguyen","year":"2012","journal-title":"Can J Cardiol"},{"key":"R2-14-20210204","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2012.40","article-title":"Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010.","volume":"307","author":"Ogden","year":"2012","journal-title":"JAMA"},{"key":"R3-14-20210204","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"R4-14-20210204","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1001\/jama.298.17.2028","article-title":"Cause-specific excess deaths associated with underweight, overweight, and obesity.","volume":"298","author":"Flegal","year":"2007","journal-title":"JAMA"},{"key":"R5-14-20210204","doi-asserted-by":"crossref","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","article-title":"Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force.","volume":"155","author":"Leblanc","year":"2011","journal-title":"Ann Intern Med"},{"key":"R6-14-20210204","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/CIRCULATIONAHA.106.676379","article-title":"International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.","volume":"116","author":"Balkau","year":"2007","journal-title":"Circulation"},{"key":"R7-14-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1098-3597(08)60024-1","article-title":"Obesity-related cardiometabolic complications.","volume":"9","author":"Cannon","year":"2008","journal-title":"Clin Cornerstone"},{"key":"R8-14-20210204","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1161\/01.CIR.0000020650.86137.84","article-title":"Obesity, metabolic syndrome, and coronary atherosclerosis.","volume":"105","author":"Grundy","year":"2002","journal-title":"Circulation"},{"key":"R9-14-20210204","first-page":"7","article-title":"Obesity and metabolic disease: is adipose tissue the culprit Proc Nutr S","volume":"64","author":"Frayn","year":"2005","journal-title":"oc"},{"key":"R10-14-20210204","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1161\/01.CIR.0000018121.67607.CE","article-title":"Obesity accelerates the progression of coronary atherosclerosis in young men.","volume":"105","author":"McGill","year":"2002","journal-title":"Circulation"},{"key":"R11-14-20210204","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies.","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet"},{"key":"R12-14-20210204","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1098-3597(09)80004-5","article-title":"Guiding clinical decisions on abdominal obesity and cardiometabolic risk.","volume":"9","author":"Nesto","year":"2009","journal-title":"Clin Cornerstone"},{"key":"R13-14-20210204","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"R14-14-20210204","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jacc.2005.11.062","article-title":"Impact of body mass index on cardiac mortality in patients with known or suspected coronary artery disease undergoing myocardial perfusion single-photon emission computed tomography.","volume":"47","author":"Kang","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R15-14-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure.","volume":"165","author":"Curtis","year":"2005","journal-title":"Arch Intern Med"},{"key":"R16-14-20210204","first-page":"1","article-title":"The obesity paradox and outcome in heart failure: is excess bodyweight truly protective Future C","volume":"6","author":"Arena","year":"2010","journal-title":"ardiol"},{"key":"R17-14-20210204","first-page":"944","article-title":"The obesity paradox: fact or fiction Am J C","volume":"98","author":"Habbu","year":"2006","journal-title":"ardiol"},{"key":"R18-14-20210204","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jama.2012.185445","article-title":"Does body mass index adequately convey a patients mortality risk","volume":"309","author":"Heymsfield","year":"2013","journal-title":"JAMA"},{"key":"R20-14-20210204","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","article-title":"Anti-obesity drugs: past, present and future.","volume":"5","author":"Rodgers","year":"2012","journal-title":"Dis Model Mech"},{"key":"R22-14-20210204","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"R23-14-20210204","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1185\/03007995.2013.794776","article-title":"Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.","volume":"29","author":"Nigro","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R24-14-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jand.2012.08.028","article-title":"Lorcaserin for weight loss: insights into US Food and Drug Administration approval.","volume":"113","author":"Miller","year":"2013","journal-title":"J Acad Nutr Diet"},{"key":"R25-14-20210204","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1185\/03007995.2013.794776","article-title":"Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.","volume":"29","author":"Nigro","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R26-14-20210204","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/obr.12015","article-title":"Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.","volume":"14","author":"Chan","year":"2013","journal-title":"Obes Rev"},{"key":"R27-14-20210204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/erc.10.22","article-title":"Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.","volume":"9","author":"Bays","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R28-14-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management.","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-14-20210204","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R30-14-20210204","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1185\/03007995.2013.794776","article-title":"Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.","volume":"29","author":"Nigro","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R31-14-20210204","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity.","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R32-14-20210204","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"R33-14-20210204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","article-title":"Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.","volume":"47","author":"Kim","year":"2006","journal-title":"Yonsei Med J"},{"key":"R34-14-20210204","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.","volume":"144","author":"Weintraub","year":"1984","journal-title":"Arch Intern Med"},{"key":"R35-14-20210204","first-page":"300","article-title":"A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.","volume":"3","author":"Valle-Jones","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"R36-14-20210204","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.1992.69","article-title":"Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R37-14-20210204","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2012.675326","article-title":"Anti-obesity drugs: a review about their effects and their safety.","volume":"11","author":"Derosa","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R38-14-20210204","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2012.675326","article-title":"Anti-obesity drugs: a review about their effects and their safety.","volume":"11","author":"Derosa","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R39-14-20210204","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/archinte.1997.00440410115015","article-title":"Phentermine--resin or salt--there are differences.","volume":"157","author":"Coyne","year":"1997","journal-title":"Arch Intern Med"},{"key":"R40-14-20210204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity.","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"R41-14-20210204","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2012.675326","article-title":"Anti-obesity drugs: a review about their effects and their safety.","volume":"11","author":"Derosa","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R42-14-20210204","first-page":"222","article-title":"Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.","volume":"17","author":"Derosa","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"R43-14-20210204","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1517\/14656566.2010.493557","article-title":"Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.","volume":"11","author":"Derosa","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R44-14-20210204","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1507\/endocrj.K10E-049","article-title":"Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.","volume":"57","author":"Derosa","year":"2010","journal-title":"Endocr J"},{"key":"R45-14-20210204","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"R46-14-20210204","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jada.2011.10.006","article-title":"Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers.","volume":"112","author":"Smith","year":"2012","journal-title":"J Acad Nutr Diet"},{"key":"R47-14-20210204","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/oby.2011.143","article-title":"Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.","volume":"19","author":"Smith","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"R48-14-20210204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF03347036","article-title":"Effects of short-term treatment with orlistat on growth hormoneinsulin-like growth factor-I axis in obese post-menopausal women.","volume":"34","author":"Di","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"R49-14-20210204","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.","volume":"24","author":"Finer","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"R50-14-20210204","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"R51-14-20210204","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-010-3409-0","article-title":"The effects of ezetimibe andor orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.","volume":"45","author":"Nakou","year":"2010","journal-title":"Lipids"},{"key":"R52-14-20210204","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/oby.2009.155","article-title":"Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).","volume":"18","author":"Kopelman","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"R53-14-20210204","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"R54-14-20210204","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","article-title":"Pharmacological treatment of the overweight patient.","volume":"59","author":"Bray","year":"2007","journal-title":"Pharmacol Rev"},{"key":"R55-14-20210204","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1242\/dmm.009621","article-title":"Anti-obesity drugs: past, present and future.","volume":"5","author":"Rodgers","year":"2012","journal-title":"Dis Model Mech"},{"key":"R56-14-20210204","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"R57-14-20210204","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.61.4.490","article-title":"Topiramate in migraine prevention: results of a large controlled trial.","volume":"61","author":"Silberstein","year":"2004","journal-title":"Arch Neurol"},{"key":"R58-14-20210204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review.","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"key":"R59-14-20210204","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity.","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"R60-14-20210204","first-page":"123","article-title":"Clinical pharmacology: drugs as a benefit andor risk in sudden unexpected death in epilepsy J Clin P","volume":"42","author":"Lathers","year":"2002","journal-title":"harmacol"},{"key":"R61-14-20210204","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dc11-1299","article-title":"Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"R62-14-20210204","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2012.675326","article-title":"Anti-obesity drugs: a review about their effects and their safety.","volume":"11","author":"Derosa","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"R63-14-20210204","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R64-14-20210204","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabet.2009.03.005","article-title":"Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.","volume":"35","author":"Fontbonne","year":"2009","journal-title":"Diabetes Metab"},{"key":"R65-14-20210204","doi-asserted-by":"crossref","first-page":"636181","DOI":"10.1155\/2011\/636181","article-title":"Present and future: pharmacologic treatment of obesity.","volume":"2011","author":"Glandt","year":"2011","journal-title":"J Obes"},{"key":"R66-14-20210204","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","article-title":"Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.","volume":"30","author":"Vilsboll","year":"2007","journal-title":"Diabetes Care"},{"key":"R67-14-20210204","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"R68-14-20210204","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"R69-14-20210204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phenterminetopiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R70-14-20210204","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"R71-14-20210204","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phenterminetopiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"R72-14-20210204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phenterminetopiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R73-14-20210204","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"R74-14-20210204","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phenterminetopiramate in severely obese adults: a randomized controlled trial (EQUIP).","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"R75-14-20210204","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"R76-14-20210204","first-page":"971","article-title":"Obesity in Europe - does anybody care Expert Opin P","volume":"14","author":"Astrup","year":"2013","journal-title":"harmacother"},{"key":"R77-14-20210204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/joim.12012","article-title":"Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery.","volume":"273","author":"Sjostrom","year":"2013","journal-title":"J Intern Med"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HCO.0b013e3283642a4c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:54:47Z","timestamp":1620953687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001573-201309000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e3283642a4c","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}